Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial
Ben George / nature - Nature Medicine, Published online: 23 October 2026; doi:10.1038/s41591-026-04734-7As presented at the ESMO Congress 2026, in a randomized phase 2 trial evaluating an off-the-shelf lymph node-targeting peptide vaccine in patients with mutated KRAS pancreat…
AI Summary: The randomized AMPLIFY‑7P phase 2 tested a lymph node‑targeted mKRAS amphiphile vaccine in resected pancreatic cancer, yielding promising immunologic responses and early signs of clinical benefit with acceptable tolerability. Investigators view the results as proof‑of‑concept that KRAS‑directed vaccines could augment adjuvant strategies and merit larger confirmatory studies.
Related Stories
KRAS vaccine shows safety and durable immune responses in high-risk individuals / 3 months
Enhertu (DESTINY‑Lung04) improves PFS in HER2‑mutant lung cancer / 2 months
Map of daraxonrasib resistance points to combo strategies in pancreatic cancer / 2 months
Engineered bacteria show promise as tumor‑targeting therapy in preclinical studies / 3 months
Daraxonrasib shows encouraging activity in NRAS-driven melanoma patients / 3 months
Rogaratinib shows activity in SDH‑deficient GIST phase 2 trial / 4 months
Phase 2 POLAR reports pembrolizumab plus olaparib outcomes in HRD pancreatic cancer / 6 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Price Transparency, Venture Capital, Weight Loss, Cancer Research and look for the RSS link.
StackHealth Time Machine